Evaluation of high sensitive C-reactive protein and 5-10 methylenetetrahydrofolate reductase genotype in Japanese young adults

Biomarkers

Volumn 9, Issue 3, 2004, Pages 291-297

  Kimura, Yuko ^a   Takamura, Noboru ^a   Fukunaga, Masato ^a   Kanagae, Mitsuo ^a   Abe, Yasuyo ^a   Aoyagi, Kiyoshi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

5 10 methylenetetrahydrofolate reductase (MTHFR); High sensitive CRP (hs CRP); School health counseling; Young Adult

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); C REACTIVE PROTEIN; GENOMIC DNA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; RISK FACTOR; SAMPLE SIZE; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 11844305995     PISSN: 1354750X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13547500400017846     Document Type: Article

References (26)

1. Barbeau, P., Litaker, M. S., Woods, K. F., Lemmon, C. R., Humphries, M. C., Owens, S. and Gutin, B. 2002, Hemostatic and inflammatory markers in obese youths: effects of exercise and adiposity. Journal of Pediatrics, 141, 415-420.
2. Cook, D. G., Mendall, M. A., Whinchup, P. H., Carey, I. M., Ballam, L., Morris, J. E., Miller, G. J. and Strachan, D. P. 2000, C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis, 149, 139-150.
3. Cushman, M., Legault, C., Barrett-Connor, E., Stefanick, M. L., Kessler, C., Judd, H. L., Sakkinen, P. A. and Tracy, R. P. 1999, Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation, 100, 717-722.
4. De Bree, A., Verschuren, W. M., Kromhout, D., Kluijtmans, L. A. and Blom, H. J. 2002, Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev, 54, 599-618.
5. Decensi, A., Omodei, U., Robertson, C., Bonanni, B., Guerrieri-Gonzaga, A., Ramazzotto, F., Johansson, H., Mora, S., Sandri, M. T., Cazzaniga, M., Franchi, M. and Pecorelli, S. 2002, Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation, 106, 1224-1228.
6. Demuth, K., Moatti, N., Hanon, O., Benott, M. O., Safar, M. and Girerd, X. 1998, Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler Thromb Vasc Biol, 18, 1838-1843.
7. Engbersen, A. M., Franken, D. G., Boers, G. H., Stevens, E. M., Trijbels, F. J. and Blom, H. J. 1995, Thermolabile 5,10- methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet, 56, 142-150.
8. Ford, E. S., Galuska, D. A., Gillespie, C., Will, J. C., Giles, W. H. and Dietz, W. H. 2001, C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Pediatr, 138, 486-492.
9. Frosst, P., Blom, H. J., Mios, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J., Den Heijer, M., Kluijtmans, L. A. and Van Den Heuvel, L. P. 1995, A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10, 111-113.
10. Haverkate, F., Thompson, S. G., Pyke, S. D., Gallimore, J. R. and Pepys, M. B. 1997, Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet, 349, 462-466.
11. Jarvisalo, M. J., Harmoinen, A., Hakanen, M., Paakkunaninen, U., Viikari, J., Hartiala, J., Lehtimaki, T., Smeli, O. and Raitakari, O. T. 2002, Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol, 22 1323-1328.
12. Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B. and Maseri, A. 1994, The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med, 331, 417-424.
13. Macy, E. M., Hayes, T. E. and Tracy, R. P. 1997, Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem, 43, 52-58.
14. Mendall, M. A., Patel, P., Ballam, L., Strachan, D. and Northfield, T. C. 1996, C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ, 312, 1061-1065.
15. Miller, A. P., Chen, Y. F., Xing, D., Feng, W. and Oparil, S. 2003, Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension, 42, 657-663.
16. Misra, A. 2000, Risk factors for atherosclerosis in young individuals. J Cardiovasc Risk, 7, 215-229.
17. Pradhan, A. D., Manson, J. E., Rossouw, J. E., Siscovick, D. S., Mouton, C. P., Rifai, N., Wallace, R. B., Jackson, R. D., Pettinger, M. B. and Ridker, P. M. 2002, Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288, 980-987.
18. Refsum, H., Ueland, P. M., Nygard, O. and Vollset, S. E. 1998, Homocysteine and cardiovascular disease. Annu Rev Med, 49 31-62.
19. Reynolds, G. D. and Vance, R. P. 1987, C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med, 111, 265-269.
20. Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. and Hennekens, C. H. 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 336, 973-979.
21. Ridker, P. M. 1998, Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation 97, 1671-1674.
22. Srinivasan, S. R., Ehnholm, C., Wattigney, W A. and Berenson, G. S. 1996, Influence of apolipoprotein E polymorphism on the tracking of childhood levels of serum lipids and apolipoproteins over a 6-year period. The Bogalusa Heart Study. Atherosclerosis, 127, 73-79.
23. Takamura, N., Kondoh, T., Ohgi, S., Arisawa, K., Mine, M., Yamashita, S. and Aoyagi, K. 2004, Abnormal folic acid/homocysteine metabolism as maternal risk factors for Down syndrome in Japan. European Journal of Nutrition, 43, 285-287.
24. Vikram, N. K., Misra, A., Dwivedi, M., Sharma, R., Pandey, R. M., Luthra, K., Chatterjee, A., Dhingra, V, Jailkhani, B. L., Talwar, K. K. and Guleria, R. 2003, Correlations of C-reactive protein levels with anthropometric profile, percentage of body fat and lipids in healthy adolescents and young adults in urban North India. Atherosclerosis, 168, 305-313.
25. Visser, M., Bouter, L. M., McQuillan, G. M., Wener, M. H. and Harris, T. B. 2001, Low-grade systemic inflammation in overweight children. Pediatrics, 107, E13-E18.
26. Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B. and Jialal, I. 2003, Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol, 41, 1358-1363.